Meena Sakharkar obtained her PhD from the National University of Singapore, followed by postdoctoral training at Stanford University. She was assistant professor with concurrent appointments as head, Pharmacogenomics and deputy director for the Advanced Design and Modeling Lab at Nanyang Technological University, Singapore. Before joining the University of Saskatchewan Dr. Sakharkar was a professor at the Graduate School of Life and Environmental Science at the University of Tsukuba, Japan.
Research
Dr. Sakharkar’s research interests are in drug target identification and validation using multiple cross-disciplinary approaches. Currently, she is developing a framework for finding novel therapeutics for metastatic breast cancer. She has published more than 70 peer-reviewed articles and has recently co-edited two books in genomics and drug discovery.
Recent Publicatons
Sakharkar KR, Sakharkar MK, and Chandra R. 2014. Post-genomic approaches in drug and vaccine development, River Publishers, Denmark.
Sakharkar KR, Sakharkar MK, and Chandra R. 2014. Post-genomic approaches in cancer and nano-medicine, River Publishers, Denmark.
Shashni B, Sharma K, Singh R, Sakharkar KR, Dhillon SK, Nagasaki Y, Sakharkar MK. Coffee component hydroxyl hydroquinone (HHQ) as a putative ligand for PPAR gamma and implications in breast cancer. BMC Genomics. 2013;14 Suppl 5:S6.
Sakharkar MK, Shashni B, Sharma K, Dhillon SK, Ranjekar PR, Sakharkar KR. Therapeutic implications of targeting energy metabolism in breast cancer. PPAR Res. 2013:109285.
Shashni B, Sakharkar KR, Nagasaki Y, Sakharkar MK. Glycolytic enzymes PGK1 and PKM2 as novel transcriptional targets of PPARγ in breast cancer pathophysiology. J Drug Target. 2013 Feb;21(2):161-74.
Jayaraman P, Sakharkar KR, Lim C, Siddiqi MI, Dhillon SK, Sakharkar MK. Novel phytochemical-antibiotic conjugates as multitarget inhibitors of Pseudomononas aeruginosa GyrB/ParE and DHFR. Drug Des Devel Ther. 2013 Jun 17; 7:449-75.
Jayaraman P, Sakharkar KR, Daniel LC, Siddiqi MI, Dhillon SK, Sakharkar MK. Hybrid-drug design targeting Pseudomonas aeruginosa DHPS and DHFR. Front Biosci (Elite Ed). 2013 Jun 1;5:864-82.
